62 results about "Gallbladder cancer" patented technology

Provided is an antibody effective for treatment and / or prevention of gallbladder cancer. A pharmaceutical composition for treatment and / or prevention of gallbladder cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.

The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

The present invention provides antibodies, which can be used as a therapeutic agent for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases, such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, Liver, head and neck, and gallbladder cancers.

The present invention provides antibodies that can be used as therapeutic agents for the treatment and / or prevention of diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, Liver, head and neck and gallbladder cancers.

The invention relates to a traditional Chinese medicine composition for hepatological surgery department, in particular to a traditional Chinese medicine composition for use after gallbladder cancer surgery and a preparation method thereof. A pharmaceutical for oral administration is prepared from the following components in parts by mass: 3-5 parts of white rhizoma Et radix polygoni-cuspidatl, 5-10 parts of poria cocos, 5-8 parts of longan, 3-5 parts of rhodiola rosea, 3-5 parts of peperomia blanda, 5-8 parts of soybean, 3-5 parts of garden burnet, 3-5 parts of radix ophiopogonis, 3-5 parts of rhizoma panacis majoris, 5-8 parts of liquorice root, 5-8 parts of water chestnut hull, 3-5 parts of gynostemma pentaphyllum, 3-5 parts of loquat, 5-8 parts of Chinese Date, 5-8 parts of Chinese angelica, 5-8 parts of pilose antler and 5-8 parts of lucid ganoderma; a pharmaceutical for external use is prepared from the following components in parts by mass: 3-5 parts of chinaroot greenbrier, 5-8 parts of tangerine pith, 3-5 parts of catbrier, 5-8 parts of resina liquidambaris, 5-8 parts of plant soot, 5-8 parts of bletilla striata, 3-5 parts of radix cynanchi bungei, 3-5 parts of thyme and 3-5 parts of lignum dalbergiae odoriferae. According to the traditional Chinese medicine composition disclosed by the invention, the pharmaceutical for oral administration is cooperated with the pharmaceutical for external use to take effect; the pharmaceutical for oral administration has the advantages of tonifying qi, promoting blood circulation and detoxication, and can facilitate effect of the pharmaceutical for external use for stopping bleeding and promoting healing; and meanwhile the pharmaceutical for external use can stop bleeding and dredging collaterals, and can facilitate effect initiation of the pharmaceutical for oral administration.

The invention discloses gallbladder cancer diagnosis and prognosis judgment marker PIM1, and also discloses a gallbladder cancer diagnosis and prognosis judgment kit, which can be used for diagnosis, prediction, detection or screening of human gallbladder cancer cell proliferation, gallbladder cancer clinical stage or gallbladder cancer cancer patient prognosis. The invention also discloses the use of the PIM1 protein inhibitor in the preparation of anti-gallbladder cancer drugs. The present invention shows that PIM1 has very important significance in clinical practice, and may become a new generation of tumor biodiagnostic markers and molecular targets for tumor treatment, and opens up the research of new targets for gallbladder cancer mainly based on PIM1. Open up a new way for the development of new anti-tumor drugs.